The Discounted Cash Flow (DCF) valuation of Biomarin Pharmaceutical Inc (BMRN) is 62.85 USD. With the latest stock price at 56.49 USD, the upside of Biomarin Pharmaceutical Inc based on DCF is 11.3%.
Based on the latest price of 56.49 USD and our DCF valuation, Biomarin Pharmaceutical Inc (BMRN) is a buy. buying Biomarin stocks now will result in a potential gain of 11.3%.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 8.8% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 39.40 - 207.23 | 62.85 |
| Upside | -30.3% - 266.8% | 11.3% |